CLDX Celldex Therapeutics

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Celldex Therapeutics to Present at Jefferies Healthcare Conference

HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "” page of the "" section of the . A replay will be available for 90 days following the event.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
04/06/2024

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-6...

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition --Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today  from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—mast cell depletion via stem cell factor (SCF) starvation and neutralization of the alarmin thymic s...

October 30, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spo...

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today  demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets ma...

September 17, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Con...

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentation will be available on the "” page of the "" section of the . A replay will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver life-changing therapies. We...

September 9, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinop...

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE Favorable safety profile demonstrated for barzolvolimab 300 mg Q4 weekly dosing regimenCompany to host webcast today at 4:30 pm ET HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today ...

August 19, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Second Quarter 2025 Financial Results and Provides Cor...

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated from Phase 2 studies of barzolvolimab in EoE and CIndU and Phase 1 study of CDX-622 in healthy volunteers in 2H 2025 HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch